Effects of Menthol on Dyspnoea in COPD Patients (MEDiC)
Effects of Menthol on Dyspnoea Induced by Exercise in COPD Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Bretagne
-
Morlaix, Bretagne, France, 29672
- Centre Hospitalier des Pays de Morlaix
-
-
Normandie
-
Le Havre, Normandie, France, 76290
- Groupe Hospitalier Du Havre
-
-
Nouvelle-Aquitaine
-
Talence, Nouvelle-Aquitaine, France, 33400
- Resp'Air
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- a diagnosis of COPD
- Dyspnea in daily living (2-4 on the modified medical research council dyspnea scale)
- Clinically stable
Exclusion Criteria:
- exercise contraindication Any musculoskeletal problems, cardiovascular or neurological comorbidities that limits exercise.
- exacerbation during the study
- Inability to chew or patients with swallowing disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Test with Menthol
Patients will chew a menthol flavored chewing gum 5 minutes before perform one Six-minute Walk Test
|
patients will perform a Six-minute walk test according to American Thoracic Society guidelines
|
|
Placebo Comparator: Test with placebo
Patients will chew a strawberry flavored chewing gum 5 minutes before perform one Six-minute Walk Test
|
patients will perform a Six-minute walk test according to American Thoracic Society guidelines
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Dyspnea after each tests
Time Frame: The outcome will be measured before and at the end of the test, the two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
Change in dyspnea using Modified Borg Scale (0 - 10 points) 0=no dyspnea ; 10 = maximal effort
|
The outcome will be measured before and at the end of the test, the two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in respiratory rate
Time Frame: Data will be continuously collected during every tests. The two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
Change in respiratory rate (cycles per minute) will be measured breath-by-breath using a Respiratory Inductive Plethysmography
|
Data will be continuously collected during every tests. The two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
|
Change in inspiratory capacity
Time Frame: The outcome will be measured before and at the end of the test, the two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
Change in inspiratory capacity (Liters) will be measured using a portable spirometer
|
The outcome will be measured before and at the end of the test, the two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
|
Change in Cardiac Frequency
Time Frame: Data will be continuously collected during every tests. The two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
Change in Cardiac Frequence (bpm) using a pulse oximetry
|
Data will be continuously collected during every tests. The two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
|
Change in Oxygen Saturation
Time Frame: Data will be continuously collected during every tests. The two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
Change in Oxygen Saturation (%) using a pulse oximetry
|
Data will be continuously collected during every tests. The two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
|
Change in tidal volume
Time Frame: The outcome will be measured before and at the end of the test, the two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
Change in tidal volume (Liters) will be measured breath-by-breath using a portable spirometer
|
The outcome will be measured before and at the end of the test, the two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
|
Change in 6-min walk distance
Time Frame: The outcome will be measured at the end of each tests. The two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
Change in 6-min walk distance (meters).
|
The outcome will be measured at the end of each tests. The two six-minute walk test will perform the same day, separate from 30 minutes minimum for a total time frame of 1 day.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Guillaume Prieur, Groupe Hospitalier Du Havre
- Principal Investigator: Marc Beaumont, Centre Hospitalier des Pays de Morlaix
- Principal Investigator: Mathieu Delorme, Resp'Air, Talence
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2018-A00585-50
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.